A Blue Day

I've come down with a virus again, it gets to my sinuses and I get achy all over. My wife had the same thing a couple weeks ago, maybe worse. It will pass but it's a disruption I could do without. Could be the rain falling the last couple of days does not help.



I find now that when I fly, I tend to get sick afterwards. Maybe it is the altitude plugging my head up, probably more like travelling disrupts my body rhythms. My digestive system is most affected. My tummy is still tender after all this time.



So, ten years out I'm more susceptible to viruses and some gastro wierdness. I'll live with it - the key word is live, I'm alive to enjoy my loved ones & interact with the world. Thanks to modern medicine.



Tom Hodgkin - if you could see me now - I'd buy you a drink & we could talk how things have changed.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap